Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Allergan plc Ordinary Shares (NYSE:AGN)’s Botox Gets FDA Approval For Third Indication

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 04:15pm CEST

Allergan plc Ordinary Shares (NYSE:AGN)’s Botox has received the approval of the U.S. Food and Drug Administration for a third indication – improving the facial appearance of adults who have particular forehead lines. Other indications for which the FDA has given approval for Botox include the treatment of glabellar lines and crow’s feet. This now makes Botox the sole neurotoxin approved for use in treating three distinct facial areas.

The decision to approve Botox for a third indication came after two clinical trials where the effectiveness of the treatment was compared to a placebo within a period of 30 days. In the first trial the primary endpoint was met by 61% of participants.

Aesthetics market

According to the chief executive officer of Allergan, Brent Saunders, the FDA approval will give the pharmaceutical company yet another opportunity in the aesthetics market which in his own words is the world’s best market.

“It’s high-quality, it’s cash-pay, it’s global. We are just at the initial stages of market development in the U.S. and almost every market in the world. So we have very high conviction around the sustainability,” Saunders is quoted as saying in an earnings call earlier in the year.

In this year’s first half, Botox generated approximately $1.53 billion in sales. This was an improvement of 12.7% compared to a year ago and was largely driven by strong demand. Now approved for the treatment of forehead lines, sales should rise even higher.

Body contouring

To bolster Allergan’s lineup in the aesthetics market, the pharmaceutical giant earlier in the year indicated that it was acquiring Zeltiq, a body contouring firm, at a price of $2.47 billion. Earlier in the year Allergan got Rhofade, a new rosacea treatment, approved. Three months ago the treatment had notched a familiarity rate of 75% among practices.

Additionally Allergan is involved in the development of Botox as a solution or particular medical cases such as prevention of chronic migraines. In Allergan’s line-up of aesthetics treatments the one product that has not been performing well is Kybella, a chin fat-buster.

On Wednesday shares of Allergan Plc fell by 0.67% to close the day at $208.39.

The post Allergan plc Ordinary Shares (NYSE:AGN)’s Botox Gets FDA Approval For Third Indication appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
06/15ALLERGAN : Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR I..
06/14ALLERGAN : Teams Up with a Host of Celebrities to Encourage Alzheimer's Patients..
06/14ABBOTT LABORATORIES : Allergan appoints former Abbott executive to its board
06/14ALLERGAN : Continues Active Board Refreshment Process
06/13ALLERGAN : Announces Positive Topline Phase 3 Clinical Data for Bimatoprost SR (..
06/13ALLERGAN : Lawsuit Filed Against Allergan for Defectively Packaged Taytulla&trad..
06/13ALLERGAN : Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy ..
06/12ALLERGAN : and Actress Shay Mitchell Join Forces to Inspire Women to Know Their ..
06/11ALLERGAN : Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy ..
More news
News from SeekingAlpha
06/15YOUR DAILY PHARMA SCOOP : Wright Receives PMA, Allergan And Corbus Report Positi.. 
06/14Allergan ticks higher as activist investors dial up the pressure for value-bo.. 
06/14Allergan continues active board refreshment process 
06/13With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis 
06/13VIKING THERAPEUTICS : Hallmark Moment 
Financials ($)
Sales 2018 15 289 M
EBIT 2018 7 368 M
Net income 2018 -1 127 M
Debt 2018 23 964 M
Yield 2018 1,59%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,41x
EV / Sales 2019 5,11x
Capitalization 58 719 M
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 206 $
Spread / Average Target 19%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC6.34%58 719
JOHNSON & JOHNSON-12.21%328 858
PFIZER-0.17%212 690
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880